Central Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $831K | Buy |
1,075
+324
| +43% | +$248K | 0.02% | 367 |
|
|
2025
Q4 | $579K | Buy |
751
+232
| +45% | +$158K | 0.01% | 411 |
|
|
2025
Q3 | $292K | Sell |
519
-673
| -56% | -$381K | 0.01% | 513 |
|
|
2025
Q2 | $626K | Sell |
1,192
-1,069
| -47% | -$597K | 0.01% | 381 |
|
|
2025
Q1 | $1.43M | Sell |
2,261
-205
| -8% | -$141K | 0.04% | 276 |
|
|
2024
Q4 | $1.76M | Buy |
2,466
+1,021
| +71% | +$857K | 0.04% | 259 |
|
|
2024
Q3 | $1.52M | Sell |
1,445
-333
| -19% | -$371K | 0.04% | 274 |
|
|
2024
Q2 | $1.87M | Sell |
1,778
-133
| -7% | -$129K | 0.05% | 237 |
|
|
2024
Q1 | $1.84M | Sell |
1,911
-61
| -3% | -$58K | 0.05% | 240 |
|
|
2023
Q4 | $1.73M | Sell |
1,972
-115
| -6% | -$94.7K | 0.05% | 242 |
|
|
2023
Q3 | $1.72M | Sell |
2,087
-613
| -23% | -$482K | 0.05% | 232 |
|
|
2023
Q2 | $1.94M | Sell |
2,700
-981
| -27% | -$756K | 0.05% | 219 |
|
|
2023
Q1 | $3.02M | Sell |
3,681
-818
| -18% | -$617K | 0.09% | 176 |
|
|
2022
Q4 | $3.25M | Sell |
4,499
-326
| -7% | -$241K | 0.1% | 171 |
|
|
2022
Q3 | $3.32M | Sell |
4,825
-72
| -1% | -$45.3K | 0.11% | 151 |
|
|
2022
Q2 | $2.89M | Sell |
4,897
-1,907
| -28% | -$1.24M | 0.1% | 169 |
|
|
2022
Q1 | $4.75M | Buy |
6,804
+196
| +3% | +$124K | 0.14% | 133 |
|
|
2021
Q4 | $4.17M | Sell |
6,608
-65
| -1% | -$40K | 0.12% | 148 |
|
|
2021
Q3 | $4.04M | Buy |
6,673
+223
| +3% | +$138K | 0.14% | 129 |
|
|
2021
Q2 | $3.6M | Sell |
6,450
-702
| -10% | -$356K | 0.13% | 141 |
|
|
2021
Q1 | $3.38M | Buy |
7,152
+4,502
| +170% | +$2.19M | 0.13% | 137 |
|
|
2020
Q4 | $1.28M | Sell |
2,650
-549
| -17% | -$296K | 0.05% | 240 |
|
|
2020
Q3 | $1.79M | Sell |
3,199
-12
| -0.4% | -$7.28K | 0.08% | 183 |
|
|
2020
Q2 | $2M | Buy |
3,211
+99
| +3% | +$56.2K | 0.1% | 159 |
|
|
2020
Q1 | $1.52M | Buy |
3,112
+37
| +1% | +$15.3K | 0.09% | 169 |
|
|
2019
Q4 | $1.16M | Sell |
3,075
-94
| -3% | -$31.6K | 0.06% | 240 |
|
|
2019
Q3 | $879K | Sell |
3,169
-1,999
| -39% | -$592K | 0.05% | 261 |
|
|
2019
Q2 | $1.51M | Buy |
5,168
+2,774
| +116% | +$924K | 0.09% | 191 |
|
|
2019
Q1 | $983K | Buy |
2,394
+2,357
| +6,370% | +$971K | 0.06% | 231 |
|
|
2018
Q4 | $14K | Hold |
37
| – | – | ﹤0.01% | 831 |
|
|
2018
Q3 | $15K | Hold |
37
| – | – | ﹤0.01% | 903 |
|
|
2018
Q2 | $13K | Hold |
37
| – | – | ﹤0.01% | 922 |
|
|
2018
Q1 | $13K | Hold |
37
| – | – | ﹤0.01% | 926 |
|
|
2017
Q4 | $14K | Sell |
37
-29
| -44% | -$11.7K | ﹤0.01% | 933 |
|
|
2017
Q3 | $30K | Sell |
66
-28
| -30% | -$13.3K | ﹤0.01% | 771 |
|
|
2017
Q2 | $46K | Buy |
94
+2
| +2% | +$875 | ﹤0.01% | 706 |
|
|
2017
Q1 | $36K | Buy |
92
+7
| +8% | +$2.6K | ﹤0.01% | 792 |
|
|
2016
Q4 | $31K | Hold |
85
| – | – | ﹤0.01% | 813 |
|
|
2016
Q3 | $34K | Sell |
85
-134
| -61% | -$53.8K | ﹤0.01% | 762 |
|
|
2016
Q2 | $76K | Buy |
219
+12
| +6% | +$4.62K | 0.01% | 580 |
|
|
2016
Q1 | $75K | Sell |
207
-2,089
| -91% | -$861K | 0.01% | 582 |
|
|
2015
Q4 | $1.25M | Sell |
2,296
-491
| -18% | -$266K | 0.1% | 178 |
|
|
2015
Q3 | $1.3M | Buy |
2,787
+2,518
| +936% | +$1.35M | 0.11% | 173 |
|
|
2015
Q2 | $137K | Sell |
269
-130
| -33% | -$63.4K | 0.01% | 487 |
|
|
2015
Q1 | $180K | Sell |
399
-440
| -52% | -$186K | 0.01% | 442 |
|
|
2014
Q4 | $344K | Sell |
839
-978
| -54% | -$385K | 0.03% | 348 |
|
|
2014
Q3 | $655K | Sell |
1,817
-143
| -7% | -$47.9K | 0.05% | 257 |
|
|
2014
Q2 | $554K | Hold |
1,960
| – | – | 0.04% | 288 |
|
|
2014
Q1 | $589K | Sell |
1,960
-5
| -0.3% | -$1.54K | 0.05% | 278 |
|
|
2013
Q4 | $541K | Sell |
1,965
-170
| -8% | -$48.9K | 0.05% | 284 |
|
|
2013
Q3 | $668K | Buy |
+2,135
| New | +$562K | 0.06% | 244 |
|
Other funds holding REGN
VCM
N
Central Trust Company's REGN Position: Q1 2026 in Review
Central Trust Company increased its Regeneron Pharmaceuticals (REGN) stake by 43% in Q1 2026, buying an estimated $248K and bringing the position to 1,075 shares worth $831K. The position accounts for 0.02% of the portfolio, ranked #367.
Central Trust Company first reported a position in REGN in Q3 2013 and has held it in 51 quarters since. The position peaked at $4.75M in Q1 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Central Trust Company held 1,075 shares of Regeneron Pharmaceuticals worth $831K as of Q1 2026.
- Central Trust Company bought 324 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $248K.
- Regeneron Pharmaceuticals made up 0.02% of Central Trust Company's portfolio in Q1 2026, its #367 holding.
- Central Trust Company first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- Central Trust Company's Regeneron Pharmaceuticals position peaked at $4.75M in Q1 2022.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.